Human IL-22 Antibody - Fezakinumab Biosimilar

Human IgG1 - CAS #1007106-86-6

ABOUT

Anti-human IL-22 - Fezakinumab biosimilar - CAS #1007106-86-6

Anti-hIL-22-hIgG1 is a biosimilar antibody of Fezakinumab, a human interleukin 22 (IL-22) antibody that blocks IL-22 signaling. This monoclonal antibody (mAb) has progressed to phase 2 clinical trials to treat patients with atopic dermatitis and rheumatoid arthritis.

More details More details 


Anti-hIL-22-hIgG1 comprises the variable region and the IgG1 constant region of Fezakinumab, mediating high effector functions. 

This antibody can be used together with HEK-Blue™ IL-22 cells for screening and neutralization assays to block signaling induced by recombinant human IL-22 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Binding of Anti-hIL-22 Fezakinumab
Binding of Anti-hIL-22 Fezakinumab

SPECIFICATIONS

Specifications

Target

IL-22

Target species

Human

Applications

Neutralization assay (tested), ELISA, ADCC

Species
Human
Isotype
hIgG1
lambda
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Fezakinumab
CAS number
1007106-86-6
Synonyms
ILV-094
Molecular weight
150 kDa
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-22-hIgG1
  • Cat code: 
    hil22-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Fezakinumab background

Fezakinumab (aka ILV-094) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human IL-22 (interleukin 22) [1, 2]. By binding to IL-22, Fezakinumab prevents it from interacting with its receptor on the surface of immune cells, thus inhibiting its downstream functions, notably the induction of inflammatory responses [2].
IL-22 is a member of the IL-10 cytokine superfamily. It is a key regulator of immunity and inflammation at mucosal surfaces. Its principal role is to maintain barrier integrity against pathogens [3-5]. IL-22 is implicated in several pathologies, including autoimmune diseases and cancer [5, 6].
Fezakinumab has been clinically evaluated as an immunosuppressive agent for the treatment of atopic dermatitis [2] and rheumatoid arthritis [7].
 

References:

1. https://drugs.ncats.io/drug/0S77U25XZ3 (accessed October 2025).
2. Guttman-Yassky, E., et al., 2018. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J. Am. Acad. Dermatol. 78: 872.
3. Wang J. et al., 2018. Aryl hydrocarbon receptor/IL-22/Stat3 signaling pathway is involved in the modulation of intestinal mucosa antimicrobial molecules by commensal microbiota in mice. Innate Immun. 24(5):297.
4. Foxall R.B., et al., 2016. Profile of interleukin-22 in gut mucosal health and disease. IJICMR. 8:1.
5. Zenewicz L.A., 2018. IL-22: There Is a Gap in Our Knowledge. Immunohorizons. 2(6):198.
6. Hernandez P., et al.,2018. A catch-22: Interleukin-22 and cancer. Eur J Immunol. 48(1):15.
7. NCT00883896. https://clinicaltrials.gov (accessed October 2025).

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?